| Literature DB >> 32141502 |
Joseph Nelson Siewe Fodjo1, Jan H F Remme2, Pierre-Marie Preux3, Robert Colebunders1.
Abstract
BACKGROUND: A high prevalence and incidence of epilepsy has been reported in onchocerciasis-endemic regions in Central and East Africa. There is compelling epidemiological evidence suggesting that this high burden is caused by onchocerciasis-associated epilepsy (OAE). We hypothesized that OAE had also occured in West African onchocerciasis foci.Entities:
Keywords: West Africa; epilepsy; ivermectin; onchocerciasis; prevalence; vector control
Year: 2020 PMID: 32141502 PMCID: PMC7320426 DOI: 10.1093/inthealth/ihaa012
Source DB: PubMed Journal: Int Health ISSN: 1876-3405 Impact factor: 2.473
Figure 1Study selection and inclusion (Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart).
Figure 2Included study sites and OCP boundaries in West Africa.
Epilepsy population-based surveys performed in West Africa
| Study site | Survey year | First author | Study population | Epilepsy prevalence (‰) | Pre-control onchocerciasis endemicity (%) | Onchocerciasis prevalence at time of survey (%) | Duration (y) of onchocerciasis control (VC/CDTI/overall) |
|---|---|---|---|---|---|---|---|
| Benin (Savalou) | 1994 | Avode | 1443 | 15.25 | 53 | NA | 6/3/6 |
| Benin (Agbogbome) | 1995 | Gbenou | 503 | 25.84 | 67 | 47.4 | 7/4/7 |
| Benin (Zinvie) | 1997 | Debrock | 3134 | 21.06 | NE | NE | NA |
| Benin (Djidja) | 2005 | Houinato | 11 668 | 12.68 | 60 | NA | 14/12/17 |
| Benin (Dangbo) | 2007 | Houinato | 737 | 31.21 | NE | NE | NA |
| Burkina Faso (Passore, Yatenga) | 1989 | Debouverie | 16 627 | 10.65 | NE | NE | NA |
| Burkina Faso (Batondo, Nyonyogo, Pabré) | 2007 | Nitiéma | 881 | 44.27 | NE | NE | NA |
| Gambia (Farafenni) | 1997 | Coleman | 16200 | 4.26 | NE | NE | NA |
| Ghana (Kintampo) | 2010 | Ae-Ngibise | 129,812 | 1.92 | 45 | NA | 26/13/34 |
| Ivory Coast (Bonon-Frefredou) | 1987 | Kouassi | 1176 | 7.65 | NE | NE | NA |
| Ivory Coast (Akoungou) | 1989 | Kouadjo | 309 | 58.25 | 51 | NA | 0 |
| Ivory Coast (M'Brou) | 1993 | Kaudjhis | 920 | 41.30 | 76 | NA | 0 |
| Liberia (Grand Bassa) | 1981 | Goudsmit | 4436 | 27.73 | 56 | NA | 0 |
| Liberia (Grand Bassa) | 1983 | Gerrits | 1673 | 49.01 | 38 | NA | 0 |
| Mali (Tyenfala, Baguineda) | 1999 | Farnarier | 5243 | 13.35 | 71 | 23 | 12/8/12 |
| Nigeria (Igbo-Ora) | 1982 | Osuntokun | 18 954 | 5.33 | 29.1 | NA | 0 |
| Nigeria (Aiyete) | 1982 | Osuntokun | 903 | 36.54 | 39.1 | NA | 0 |
| Nigeria (Udo) | 1989 | Longe | 2925 | 6.15 | 34.4 | NA | 0 |
| Nigeria (Imo River basin) | 2004 | Dozie | 4854 | 11.95 | 49 | 26.8 | 0/5/5 |
| Nigeria (Izzi, Ebonyi state) | 2007 | Osakwe | 2500 | 20.80 | 49.4 | NA | 0/8/8 |
| Nigeria (Otukpo, Benue state) | 2007 | Osakwe | 6000 | 4.67 | 48 | NA | 0/8/8 |
| Nigeria (Ukpo) | 2010 | Nwani | 6800 | 4.26 | 44.5 | NA | 0/11/11 |
| Nigeria (Ilie, Osun state) | 2013 | Mustapha | 2212 | 4.52 | 32.5 | NA | 0/14/14 |
| Nigeria (Imo River basin) | 2018 | Siewe | 843 | 4.74 | 51 | 4.6 | 0/19/19 |
| Senegal (Moyenne vallée) | 1962 | Boutillier | 32 300 | 1.92 | NE | NE | NA |
| Senegal (Casamance, Koalack, Thiès) | 1982 | Ndiaye | 7682 | 8.33 | NE | NE | NA |
| Senegal (Pikine) | 2004 | Ndoye | 4500 | 14.22 | NE | NE | NA |
| Togo (Kloto) | 1989 | Balogou | 19 241 | 12.32 | 49 | NA | 0 |
| Togo (Akebou) | 1995 | Balogou | 4182 | 13.15 | 55 | NA | 7/0/7 |
| Togo (Tone) | 1995 | Balogou | 9155 | 18.57 | 71 | NA | 18/0/18 |
| Togo (Batamariba) | 2001 | Balogou | 6249 | 15.68 | 76 | NA | 24/10/24 |
NE: non-endemic; NA: not available
aVC/CDTI/overall: number of years of vector control/community-directed treatment with ivermectin/total duration of onchocerciasis control irrespective of the method
bReported by Wyatt (1971).
Figure 3Age of persons with epilepsy and ages at seizure onset in southern Ivory Coast.
Figure 4Forest plot and pooled epilepsy prevalence (per thousand) in the West African study sites.
Figure 5Subgroup analysis of the epilepsy prevalence stratified by duration of onchocerciasis control.
Multiple linear regression model investigating the factors associated with epilepsy prevalence in the study sites
| Model | Logit regression coefficient | 95% confidence interval | P-value | |
|---|---|---|---|---|
| Intercept | −6.343 | −7.204 | −5.483 | <0.001 |
| Pre-control onchocerciasis endemicity (prevalence of microfiladermia) | 0.046 | 0.030 | 0.063 | <0.001 |
| Duration of onchocerciasis control (years) | −0.059 | −0.076 | −0.042 | <0.001 |
aAdjusted R2=0.782.
Figure 6Plots and lines showing the relationship between epilepsy and pre-control onchocerciasis endemicity, taking into account the duration of onchocerciasis control in each endemic study site. (A) Logit-transformed scale for epilepsy prevalence. (B) Linear scale for epilepsy prevalence. The solid line represents the previously published curve by Pion et al.; the black dotted line represents endemic sites with no control measures; the blue dotted line represents sites with 1–9 y of onchocerciasis control, which is almost superimposed on the previously published curve by Pion et al.; the red dotted line shows a downward shift of epilepsy prevalence in sites with ≥10 y of onchocerciasis control. (mf: detectable O. volvulus microfilariae in skin snips.)